WEE1 and head and neck squamous cell carcinoma: The wee-1 inhibitor—AZD1775—in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in HNSCC had promising findings that may be translated into an innovative therapeutic approach (39).